Tenaya Therapeutics, Inc. (TNYA) shareholders
Close on Nov 17, 2026Market cap $72.38MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tim Kutzkey Joint filing with Peter Svennilson (25.40%), The Column Group Opportunity III, LP (23.10%) and 2 more | 54,313,559 | 25.40% | 13D (active) amendment | Feb 10, 2026 |
| Peter Svennilson Joint filing with The Column Group Opportunity III, LP (23.10%), The Column Group Opportunity III GP, LP (23.10%) and 2 more | 49,313,559 | 23.10% | 13D (active) amendment | Feb 25, 2026 |
| TCG Opportunity III GP, LLC Joint filing with The Column Group Opportunity III, LP (23.10%), The Column Group Opportunity III GP, LP (23.10%) | 49,313,559 | 23.10% | 13D (active) amendment | Dec 15, 2025 |
| The Column Group Opportunity III GP, LP Joint filing with The Column Group Opportunity III, LP (30.30%), TCG Opportunity III GP, LLC (30.30%) and 1 more | 49,313,559 | 30.30% | 13D (active) amendment | May 7, 2025 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.20%), Israel A. Englander (5.20%) and 1 more | 11,581,565 | 5.20% | 13G (passive) | Aug 17, 2026 |
| Martin D. Hoe Joint filing with Empery Asset Management, LP (9.96%), Ryan M. Lane (9.96%) | 8,727,314 | 9.96% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TNYA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 7,101,263 | 3.17% | $5.25M | −1,381,025 | 0.00% |
| Millennium Management LLC | 6,429,648 | 2.87% | $4.75M | +972,982 | 0.00% |
| Citadel Advisors LLC | 4,566,774 | 2.04% | $3.38M | +366,774 | 0.00% |
| Renaissance Technologies LLC | 4,281,100 | 1.91% | $3.16M | +567,339 | 0.00% |
| BlackRock, Inc. | 4,008,719 | 1.79% | $2.96M | +304,764 | 0.00% |
| Empery Asset Management, LP | 3,863,115 | 1.72% | $2.86M | −423,818 | 3.30% |
| Marshall Wace, Llp | 3,503,178 | 1.56% | $2.59M | +797,788 | 0.00% |
| Gsa Capital Partners Llp | 2,669,033 | 1.19% | $1.97M | +1,596,122 | 0.12% |
| Burkehill Global Management, LP | 2,000,000 | 0.89% | $1.48M | – | 0.05% |
| Geode Capital Management, LLC | 1,834,674 | 0.82% | $1.36M | +274,735 | 0.00% |
| ADAR1 Capital Management, LLC | 1,555,500 | 0.69% | $1.15M | +47,700 | 0.05% |
| Raiffeisen Bank International AG | 1,200,000 | 0.54% | $881.88K | +200,000 | 0.01% |
| Euclidean Capital LLC | 1,015,705 | 0.45% | $750.71K | – | 0.17% |
| Vanguard Fiduciary Trust Co | 987,505 | 0.44% | $729.77K | −28,197 | 0.00% |
| Mirador Capital Partners LP | 905,097 | 0.40% | $668.96K | +18,180 | 0.08% |
| State Street Corp | 708,721 | 0.32% | $523.82K | – | 0.00% |
| Squarepoint Ops LLC | 659,247 | 0.29% | $487.25K | +310,979 | 0.00% |
| StepStone Group LP | 462,163 | 0.21% | $341.54K | – | 0.02% |
| UBS Group AG | 456,555 | 0.20% | $337.39K | −208,625 | 0.00% |
| Jane Street Group, LLC | 450,435 | 0.20% | $332.92K | −729,646 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 101 | 54M | 24.0% | 18 / 32 | 17 / 19 | 7M | 10M |
| Q1 2026 | 103 | 56M | 25.1% | 26 / 33 | 18 / 19 | 19M | 23M |
| Q4 2025 | 98 | 69M | 30.6% | 28 / 30 | 20 / 18 | 37M | 3M |
| Q3 2025 | 91 | 35M | 15.4% | 20 / 14 | 32 / 17 | 7M | 5M |
| Q2 2025 | 89 | 32M | 14.2% | 20 / 25 | 23 / 38 | 5M | 22M |
| Q1 2025 | 107 | 49M | 21.7% | 31 / 22 | 32 / 10 | 11M | 6M |
| Q4 2024 | 88 | 44M | 19.6% | 22 / 29 | 19 / 28 | 10M | 22M |
| Q3 2024 | 95 | 58M | 25.7% | 17 / 37 | 18 / 17 | 7M | 3M |
| Q2 2024 | 96 | 57M | 25.5% | 18 / 37 | 28 / 12 | 5M | 4M |
| Q1 2024 | 90 | 57M | 25.3% | 24 / 27 | 26 / 7 | 13M | 3M |
| Q4 2023 | 74 | 47M | 20.9% | 10 / 28 | 24 / 12 | 2M | 6M |
| Q3 2023 | 76 | 51M | 22.6% | 11 / 32 | 13 / 14 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
21 funds held TNYA in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TNYA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,136,220 | 2.29% | $3.80M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,768,551 | 0.79% | $1.31M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,490,588 | 0.66% | $1.10M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 824,295 | 0.37% | $716.31K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 303,128 | 0.14% | $263.42K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 231,319 | 0.10% | $201.02K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 221,893 | 0.10% | $164.27K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 175,000 | 0.08% | $129.34K | 0.09% | Jun 30, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 161,857 | 0.07% | $119.63K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 120,429 | 0.05% | $104.65K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 113,232 | 0.05% | $83.69K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 83,260 | 0.04% | $61.54K | 0.00% | Jun 30, 2026 |
| T. Rowe Price Total Equity Market Index Fund | 31,453 | 0.01% | $23.25K | 0.00% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 24,395 | 0.01% | $18.06K | 0.00% | Jul 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 11,421 | 0.01% | $9.92K | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Faraz Ali | Chief Executive Officer, Director | 539,782 | 0.24% | Sep 11, 2026 |
| Whittemore Tingley | Chief Medical Officer | 263,073 | 0.12% | Sep 11, 2026 |
| Eric J. Hyllengren | Chief Financial Officer | – | – | Jul 14, 2026 |
| Tomohiro Higa | SVP, Finance | 118,267 | 0.05% | May 19, 2026 |
| Karah Herdman Parschauer | Director | – | – | May 29, 2026 |
| R. Sanders Williams | Director | 29,999 | 0.01% | May 29, 2026 |
| Catherine Stehman-Breen | Director | 8,125 | 0.00% | May 29, 2026 |
| June Lee | Director | – | – | May 29, 2026 |
| Jeffrey T. Walsh | Director | – | – | May 29, 2026 |
| Deepak Srivastava | Director | 564,101 | 0.25% | May 29, 2026 |
| Amy L. Burroughs | Director | – | – | May 29, 2026 |
| David V. Goeddel | Director, 10% owner | 49,313,559 | 21.99% | May 30, 2025 |
| Tim Kutzkey | 10% owner | – | – | Feb 26, 2026 |
| TCG Opportunity III GP, LLC | 10% owner | 0 | – | Feb 26, 2026 |
| Column Group Opportunity III, LP | 10% owner | – | – | Feb 26, 2026 |
| Peter Svennilson | 10% owner | – | – | Feb 26, 2026 |
| Column Group Iii Gp, Lp | 10% owner | 14,855,844 | 6.63% | Feb 26, 2026 |
| Column Group Iii-A, Lp | 10% owner | 1,958,509 | 0.87% | Feb 26, 2026 |
| Column Group Iii, Lp | 10% owner | 49,313,559 | 21.99% | Feb 26, 2026 |
| Column Group Opportunity III GP, LP | 10% owner | – | – | Feb 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Faraz Ali Chief Executive Officer, Director | Sep 10, 2026 | Award | +122,000 | – | – | 539,782 |
| Whittemore Tingley Chief Medical Officer | Sep 10, 2026 | Award | +49,000 | – | – | 263,073 |
| Whittemore Tingley Chief Medical Officer | Aug 17, 2026 | Sale | −1,637 | $0.71 | $1.16K | 218,223 |
| Whittemore Tingley Chief Medical Officer | Aug 17, 2026 | Sale | −2,279 | $0.71 | $1.62K | 214,073 |
| Whittemore Tingley Chief Medical Officer | Aug 17, 2026 | Sale | −1,871 | $0.71 | $1.33K | 216,352 |
| Whittemore Tingley Chief Medical Officer | Aug 17, 2026 | Sale | −1,637 | $0.71 | $1.16K | 219,860 |
| Faraz Ali Chief Executive Officer, Director | Aug 17, 2026 | Sale | −3,969 | $0.71 | $2.82K | 430,208 |
| Faraz Ali Chief Executive Officer, Director | Aug 17, 2026 | Sale | −5,837 | $0.71 | $4.14K | 434,177 |
| Faraz Ali Chief Executive Officer, Director | Aug 17, 2026 | Sale | −7,406 | $0.71 | $5.26K | 417,782 |
| Faraz Ali Chief Executive Officer, Director | Aug 17, 2026 | Sale | −5,020 | $0.71 | $3.56K | 425,188 |
| Tomohiro Higa SVP, Finance | May 18, 2026 | Sale | −1,485 | $0.79 | $1.17K | 118,267 |
| Faraz Ali Chief Executive Officer, Director | May 18, 2026 | Sale | −3,390 | $0.79 | $2.68K | 440,014 |
| Whittemore Tingley Chief Medical Officer | May 18, 2026 | Sale | −3,121 | $0.79 | $2.47K | 215,497 |
| TCG Opportunity III GP, LLC 10% owner | Feb 25, 2026 | Sale | −1,862,545 | $0.56 | $1.04M | 0 |
| TCG Opportunity III GP, LLC 10% owner | Feb 25, 2026 | Sale | −1,649,281 | $0.56 | $923.60K | 0 |
| TCG Opportunity III GP, LLC 10% owner | Feb 24, 2026 | Sale | −309,228 | $0.62 | $191.72K | 1,649,281 |
| TCG Opportunity III GP, LLC 10% owner | Feb 24, 2026 | Sale | −349,212 | $0.62 | $216.51K | 1,862,545 |
| Column Group Iii-A, Lp 10% owner | Feb 23, 2026 | Sale | −143,709 | $0.60 | $86.23K | 1,958,509 |
| Column Group Iii-A, Lp 10% owner | Feb 23, 2026 | Sale | −162,291 | $0.60 | $97.37K | 2,211,757 |
| Column Group Iii-A, Lp 10% owner | Feb 20, 2026 | Sale | −245,965 | $0.61 | $150.04K | 2,102,218 |
| Column Group Iii-A, Lp 10% owner | Feb 20, 2026 | Sale | −277,769 | $0.61 | $169.44K | 2,374,048 |
| Whittemore Tingley Chief Medical Officer | Feb 17, 2026 | Sale | −1,642 | $0.64 | $1.05K | 222,136 |
| Whittemore Tingley Chief Medical Officer | Feb 17, 2026 | Sale | −1,876 | $0.64 | $1.20K | 218,618 |
| Whittemore Tingley Chief Medical Officer | Feb 17, 2026 | Sale | −1,642 | $0.64 | $1.05K | 220,494 |
| Faraz Ali Chief Executive Officer, Director | Feb 17, 2026 | Sale | −3,979 | $0.64 | $2.55K | 448,436 |
| Faraz Ali Chief Executive Officer, Director | Feb 17, 2026 | Sale | −5,851 | $0.64 | $3.74K | 452,415 |
| Faraz Ali Chief Executive Officer, Director | Feb 17, 2026 | Sale | −5,032 | $0.64 | $3.22K | 443,404 |
| Tomohiro Higa SVP, Finance | Feb 17, 2026 | Sale | −611 | $0.64 | $391 | 122,610 |
| Tomohiro Higa SVP, Finance | Feb 17, 2026 | Sale | −2,022 | $0.64 | $1.29K | 119,752 |
| Tomohiro Higa SVP, Finance | Feb 17, 2026 | Sale | −836 | $0.64 | $535 | 121,774 |
| Column Group Iii-A, Lp 10% owner | Feb 11, 2026 | Sale | −1,905,115 | $0.68 | $1.30M | 2,348,183 |
| Column Group Iii-A, Lp 10% owner | Feb 11, 2026 | Sale | −2,151,458 | $0.68 | $1.46M | 2,651,817 |
| Column Group Iii-A, Lp 10% owner | Feb 10, 2026 | Sale | −182,295 | $0.82 | $149.48K | 4,803,275 |
| Column Group Iii-A, Lp 10% owner | Feb 10, 2026 | Sale | −161,422 | $0.82 | $132.37K | 4,253,298 |
| Faraz Ali Chief Executive Officer, Director | Feb 3, 2026 | Award | +158,600 | – | – | 458,266 |
| Tomohiro Higa SVP, Finance | Feb 3, 2026 | Award | +29,250 | – | – | 123,221 |
| Whittemore Tingley Chief Medical Officer | Feb 3, 2026 | Award | +48,750 | – | – | 223,778 |
| Whittemore Tingley Chief Medical Officer | Nov 17, 2025 | Sale | −2,877 | $1.33 | $3.83K | 169,926 |
| Faraz Ali Chief Executive Officer, Director | Nov 17, 2025 | Sale | −3,126 | $1.33 | $4.16K | 299,666 |
| Tomohiro Higa SVP, Finance | Nov 17, 2025 | Sale | −1,367 | $1.33 | $1.82K | 93,971 |
| Faraz Ali Chief Executive Officer, Director | Aug 18, 2025 | Sale | −4,920 | $1.25 | $6.15K | 302,792 |
| Faraz Ali Chief Executive Officer, Director | Aug 18, 2025 | Sale | −3,893 | $1.25 | $4.87K | 307,712 |
| Faraz Ali Chief Executive Officer, Director | Aug 18, 2025 | Sale | −5,720 | $1.25 | $7.15K | 311,605 |
| Whittemore Tingley Chief Medical Officer | Aug 18, 2025 | Sale | −1,837 | $1.25 | $2.30K | 172,803 |
| Whittemore Tingley Chief Medical Officer | Aug 18, 2025 | Sale | −1,608 | $1.25 | $2.01K | 174,640 |
| Whittemore Tingley Chief Medical Officer | Aug 18, 2025 | Sale | −1,608 | $1.25 | $2.01K | 176,248 |
| Tomohiro Higa SVP, Finance | Aug 18, 2025 | Sale | −523 | $1.25 | $654 | 97,777 |
| Tomohiro Higa SVP, Finance | Aug 18, 2025 | Sale | −717 | $1.25 | $896 | 97,060 |
| Tomohiro Higa SVP, Finance | Aug 18, 2025 | Sale | −1,722 | $1.25 | $2.15K | 95,338 |
| Whittemore Tingley Chief Medical Officer | May 16, 2025 | Sale | −2,937 | $0.44 | $1.29K | 171,856 |
| Tomohiro Higa SVP, Finance | May 16, 2025 | Sale | −1,390 | $0.44 | $612 | 98,300 |
| Faraz Ali Chief Executive Officer, Director | May 16, 2025 | Sale | −3,189 | $0.44 | $1.40K | 317,325 |
| Faraz Ali Chief Executive Officer, Director | Mar 10, 2025 | Sale | −5,794 | $0.54 | $3.13K | 324,461 |
| Faraz Ali Chief Executive Officer, Director | Mar 10, 2025 | Sale | −3,947 | $0.54 | $2.13K | 320,514 |
| Whittemore Tingley Chief Medical Officer | Mar 10, 2025 | Sale | −4,073 | $0.54 | $2.20K | 176,391 |
| Whittemore Tingley Chief Medical Officer | Mar 10, 2025 | Sale | −1,727 | $0.54 | $933 | 180,464 |
| Whittemore Tingley Chief Medical Officer | Mar 10, 2025 | Sale | −1,598 | $0.54 | $863 | 174,793 |
| Tomohiro Higa SVP, Finance | Mar 10, 2025 | Sale | −620 | $0.54 | $335 | 100,535 |
| Tomohiro Higa SVP, Finance | Mar 10, 2025 | Sale | −845 | $0.54 | $456 | 99,690 |
| Tomohiro Higa SVP, Finance | Mar 10, 2025 | Sale | −1,017 | $0.54 | $549 | 101,155 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tenaya Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 102,802 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Faraz Ali Officer, Director | Aug 17, 2026 | 22,232 | $15.78K | Aug 17, 2026 | Restricted Stock Unit |
| Whittemore Tingley Officer | Aug 17, 2026 | 7,424 | $5.27K | Aug 17, 2026 | Restricted Stock Unit |
| Column Group Iii, Lp 10% Stockholder | Feb 25, 2026 | 939,273 | $565.44K | Feb 25, 2026 | Series A financing |
| Column Group Iii, Lp 10% Stockholder | Feb 25, 2026 | 1,060,727 | $596.55K | Feb 25, 2026 | Series B financing |
| Column Group Iii, Lp 10% Stockholder | Feb 20, 2026 | 1,408,910 | $872.54K | Feb 20, 2026 | Series A financing |
| Column Group Iii, Lp 10% Stockholder | Feb 20, 2026 | 1,591,090 | $985.36K | Feb 20, 2026 | Series A financing |
| Whittemore Tingley Officer | Feb 17, 2026 | 5,160 | $3.32K | Feb 17, 2026 | Restricted Stock Unit |
| Faraz Ali Officer, Director | Feb 17, 2026 | 14,862 | $9.56K | Feb 17, 2026 | Restricted Stock Unit |
| Column Group Iii, Lp 10% Stockholder | Feb 11, 2026 | 742,663 | $504.79K | Feb 11, 2026 | Series A financing |
| Column Group Iii, Lp 10% Stockholder | Feb 11, 2026 | 657,627 | $446.99K | Feb 11, 2026 | Series A financing |
| Column Group Iii, Lp 10% Stockholder | Feb 10, 2026 | 1,408,910 | $1.11M | Feb 10, 2026 | Series A financing |
| Column Group Iii, Lp 10% Stockholder | Feb 10, 2026 | 1,591,090 | $1.26M | Feb 10, 2026 | Series A financing |
| Whittemore Tingley Officer | Aug 18, 2025 | 5,053 | $6.33K | Aug 18, 2025 | Restricted Stock Unit |
| Faraz Ali Officer, Director | Aug 18, 2025 | 14,533 | $18.21K | Aug 18, 2025 | Restricted Stock Unit |
| Faraz Ali Officer, Director | Mar 10, 2025 | 9,741 | $5.24K | Mar 10, 2025 | Restricted Stock Unit |
See a number that looks wrong?